Exchange: NYSE·Updated 07:56 PM EDT
News
all
press releases
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
Zacks
More News
Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline
ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.
Zacks
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
$1000 Invested In McKesson 5 Years Ago Would Be Worth This Much Today
McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 23.04% on an annualized basis producing an average annual return of 34.84%. Currently, McKesson has a market capitalization of $101.38 billion.read more...
Benzinga
Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?
Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Zacks
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
Zacks
Rigetti Q2 Earnings Miss Estimates on Higher Costs, Revenue Beat
RGTI's Q2 revenues surge 185.3% and beat estimates, but widening losses and higher R&D and SG&A costs continue to pressure profitability.
Zacks
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Zacks
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Zacks

Advertisement|Remove ads.